PET/CT imaging correlates with treatment outcome in patients with multidrug-resistant tuberculosis.

Journal: Science Translational Medicine

Definitive clinical trials of new chemotherapies for treating tuberculosis (TB) require following subjects until at least 6 months after treatment discontinuation to assess for durable cure, making these trials expensive and lengthy. Surrogate endpoints relating to treatment failure and relapse are currently limited to sputum microbiology, which has limited sensitivity and specificity. We prospectively assessed radiographic changes using 2-deoxy-2-[(18)F]-fluoro-D-glucose (FDG) positron emission tomography/computed tomography (PET/CT) at 2 and 6 months (CT only) in a cohort of subjects with multidrug-resistant TB, who were treated with second-line TB therapy for 2 years and then followed for an additional 6 months. CT scans were read semiquantitatively by radiologists and were computationally evaluated using custom software to provide volumetric assessment of TB-associated abnormalities. CT scans at 6 months (but not 2 months) assessed by radiologist readers were predictive of outcomes, and changes in computed abnormal volumes were predictive of drug response at both time points. Quantitative changes in FDG uptake 2 months after starting treatment were associated with long-term outcomes. In this cohort, some radiologic markers were more sensitive than conventional sputum microbiology in distinguishing successful from unsuccessful treatment. These results support the potential of imaging scans as possible surrogate endpoints in clinical trials of new TB drug regimens. Larger cohorts confirming these results are needed.

Ray Chen, Lori Dodd, Myungsun Lee, Praveen Paripati, Dima Hammoud, James Mountz, Doosoo Jeon, Nadeem Zia, Homeira Zahiri, M Coleman, Matthew Carroll, Jong Lee, Yeon Jeong, Peter Herscovitch, Saher Lahouar, Michael Tartakovsky, Alexander Rosenthal, Sandeep Somaiyya, Soyoung Lee, Lisa Goldfeder, Ying Cai, Laura Via, Seung-kyu Park, Sang-nae Cho, Clifton Barry